Thrombosis and priapism in a patient with Henoch-Schonlein purpura

Sarı, İ̇smail; Akar, Servet; Seçil, Mustafa; Bırlık, Merih; Kefi, Aykut; Önen, Fatoş; Çelebi, İlhan; Akkoç, Nurullah

doi:10.1007/s00296-004-0532-3

Cited by 16 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Venous sinus thrombosis has been described in an adolescent who had just recovered from HSP; this VTE occurred in the setting of a positive test for the lupus anticoagulant [48]. Bilateral lower extremity DVTs was recently reported in an adult with HSP and the prothrombin 20210A mutation [49]. Acute arterial thrombosis has been reported with HSP in the setting of positive antiphospholipid antibodies [50].…”

Section: Thrombosis In Other Vasculitidesmentioning

confidence: 99%

Thromboembolic disease in vasculitis

Tómasson

Monach

Merkel

2009

Current Opinion in Rheumatology

View full text Add to dashboard Cite

Purpose of review To give an overview of recent clinical findings of thromboembolic disease in vasculitis and provide insight into possible explanations of the association between thrombosis and inflammation. Recent findings A high incidence of venous thrombotic events has recently been described in four distinct cohorts of patients with antineutrophil cytoplasmic antibodies-associated vasculitis (AAV), especially during periods of active disease. No factors other than the vasculitis itself have been identified that explain this high occurrence of thrombosis. Several studies have shown an increased rate of thrombosis in Behçet’s disease, with a different clinical presentation than that observed in AAV. Recent laboratory findings provide exciting insights into a bidirectional feedback loop between coagulation and inflammation that may be applicable to vasculitis. Summary Thrombosis is an important clinical manifestation of some types of vasculitis. Better understanding of the association of thrombosis with inflammation in vasculitis might lead to development of clinically useful biomarkers and new approaches to therapy. Additionally, study of the specific factors involved in thrombosis in systemic vasculitis could help explain the role of inflammation in more common settings of venous thrombotic events.

show abstract

Section: Thrombosis In Other Vasculitidesmentioning

confidence: 99%

Thromboembolic disease in vasculitis

Tómasson

Monach

Merkel

2009

Current Opinion in Rheumatology

View full text Add to dashboard Cite

show abstract

“…Other outcomes associated with IgAV are unknown. Multiple case reports have raised the possibility of associations between IgAV and venous thromboembolism (VTE), hypertension and ischaemic heart disease (IHD) in both children and adults 8–19. However, many cases involved patients with additional risk factors, making the role of IgAV unclear.…”

Section: Introductionmentioning

confidence: 99%

Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data

et al. 2018

View full text Add to dashboard Cite

BackgroundIgA vasculitis (IgAV, Henoch-Schönlein purpura) is a small-vessel vasculitis most common in children but also occurring in adults. Case series have suggested that IgAV may be associated with cardiovascular disease and venous thromboembolism, but this has not been evaluated in population-based studies. Renal disease and hypertension are possible complications of the disease with unknown incidence.MethodsUsing a large UK primary care database, we conducted an open retrospective matched cohort study of cardiovascular, venous thrombotic and renal outcomes in adult-onset and childhood-onset IgAV. Control participants were selected at a 2:1 ratio, matched for age and sex. Adjusted HRs (aHRs) were calculated using Cox proportional hazards models.Results2828 patients with adult-onset IgAV and 10 405 patients with childhood-onset IgAV were compared with age-matched and sex-matched controls. There was significantly increased risk of hypertension (adult-onset aHR 1.42, 95% CI 1.19 to 1.70, p < 0.001; childhood-onset aHR 1.52, 95% CI 1.22 to 1.89, p < 0.001) and stage G3–G5 chronic kidney disease (adult-onset aHR 1.54, 95% CI 1.23 to 1.93, p < 0.001; childhood-onset aHR 1.89, 95% CI 1.16 to 3.07, p=0.010). There was no evidence of association with ischaemic heart disease, cerebrovascular disease or venous thromboembolism. All-cause mortality was increased in the adult-onset IgAV cohort compared with controls (aHR 1.27, 95% CI 1.07 to 1.50, p=0.006).ConclusionsPatients with IgAV are at increased risk of hypertension and chronic kidney disease (CKD) compared with individuals without IgAV; analysis restricted to adult-onset IgAV patients showed increased mortality. Appropriate surveillance and risk factor modification could improve long-term outcomes in these patients.

show abstract

“…Thrombosis and priapism are rarely reported secondary to HSP. Sari et al [32] described a patient that presented with thrombosis and priapism after being diagnosed with HSP. The case was a 37-year-old male who experienced penile thrombosis repeatedly after developing HSP, resulting in priapism.…”

Section: Urological Manifestationsmentioning

confidence: 99%

Urological Manifestations of Henoch-Schonlein Purpura: A Review

et al. 2015

View full text Add to dashboard Cite

Henoch-Schonlein purpura (HSP) is an immune-mediated systemic vasculitis generally found in children. The standard manifestations of HSP are palpable purpura, arthritis, abdominal pain, and renal complications. Although less common, there are significant urological manifestations associated with HSP. The primary objective of this review is to encourage better understanding and management of HSP by emphasizing the common and rare manifestations of HSP, how they are diagnosed, and the latest treatment options for mild to severe complications. Medline searches of HSP and its urological manifestations were conducted along with searches on current diagnostic and treatment methods. Urological manifestations of HSP involve the kidney, ureter, bladder, prostate, scrotum, testicle, and penis. Diagnosis and management of HSP are not always clear due to differential diagnosis and diversity of symptom presentation. Treatment for HSP is mainly supportive and includes use of nonsteroidal anti-inflammatory drugs for pain relief. In more severe cases, glucocorticoids, methylprednisolone, plasmapheresis, and peritoneal and hemodialysis are reported successful. It is important to note different symptoms of HSP in order to distinguish HSP from other diseases. Early diagnosis may prevent severe complications. Treatment options vary from conservative to invasive depending on the severity of the disease and time frame of diagnosis.

show abstract

Thrombosis and priapism in a patient with Henoch-Schonlein purpura

Cited by 16 publications

References 20 publications

Thromboembolic disease in vasculitis

Thromboembolic disease in vasculitis

Cardiovascular, thromboembolic and renal outcomes in IgA vasculitis (Henoch-Schönlein purpura): a retrospective cohort study using routinely collected primary care data

Urological Manifestations of Henoch-Schonlein Purpura: A Review

Contact Info

Product

Resources

About